CTOs on the Move

Actavis

www.actavis.com

 
Actavis is a unique global specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world. The Company has global headquarters in Dublin, Ireland. Actavis markets a broad portfolio of branded pharmaceuticals and is focused on developing new medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. Actavis is also the world`s third-largest generics prescription drug manufacturer, marketing generic, branded generic, and Over-the-Counter (OTC) products in more than 60 countries. Actavis Global Operations has more than 35 ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.actavis.com
  • 400 Interpace Pkwy
    Parsippany, NY USA 07054
  • Phone: 862.261.7000

Executives

Name Title Contact Details

Similar Companies

Bio-Pharm Inc

Bio-Pharm Inc is a Levittown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Life Centers

Life Centers Incorporated is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meda

Meda is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Theradex Oncology Experts

Theradex is an international contract research organization providing complete professional services for the clinical research and development of pharmaceutical compounds, medical devices and diagnostic tests in the areas of oncology and

Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera`s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus.